Search

After showing for the first time the potential of an anti-tau therapy in Alzheimer's disease, Roche-partnered AC Immune is capitalizing on the massive moment underway in research for the neurodegenerative disease. [ABSTRACT FROM AUTHOR]

Roche's Genentech has signed what could be a $670 million deal for Lineage Cell Therapeutics' cell therapy for a range of eye disorders. Lineage is developing a retinal pigment epithelium cell therapy in dry age-related macular degeneration with geographic atrophy. [ABSTRACT FROM AUTHOR]

Fierce Biotech profiles three women breaking barriers in Alzheimer's disease R&D at leading pharmaceutical companies. Today, Genentech's global head of neurodegeneration, Rachelle Doody. [ABSTRACT FROM AUTHOR]

As Fierce Biotech reported out the aftermath of the controversial approval of Biogen's Aduhelm, we discovered a common thread at many of the top pharma companies who are working on the most advanced treatments in development: women. We wanted to know—how have they kept going? [ABSTRACT FROM AUTHOR]

Are seaweed-controlled oral cell therapies the future of inflammatory bowel disease therapy? That is the question posed by the latest deal from Genentech, which is teaming up with Novome Biotechnologies to study a novel approach to the indication. [ABSTRACT FROM AUTHOR]

The Novartis Institutes for BioMedical Research's oncology department has poached Genentech's Shiva Malek, Ph.D., to help lead its cancer research. [ABSTRACT FROM AUTHOR]

Roche's biotech arm Genentech has created a new coalition of clinical research sites aimed at boosting diversity in oncology studies. [ABSTRACT FROM AUTHOR]

Neogene snared a longtime BMS leader, courtesy of its quick entry into the next-gen cell therapy space. Tectonic is building out its C-suite roster with a 16-year veteran of the Genomics Institute of the Novartis Research Foundation. And Guardant Health has added oncology drug development bigwig Craig Eagle to its ranks. [ABSTRACT FROM AUTHOR]

Replimune has snagged Genentech oncology vet Sushil Patel to fill the CCO seat. Humanigen has opened up a CMO role and picked an AstraZeneca vet to fill it. Gossamer Bio's chief scientist will depart for pastures new. [ABSTRACT FROM AUTHOR]

AltruBio would like to reintroduce itself. After shifting from oncology to immunology, swapping out the board and completing a name change, the biotech is relaunching with a $63 million Series A funding round. [ABSTRACT FROM AUTHOR]

Genentech and Roche have partnered with the University of California (UC), San Francisco and UC Berkeley to work on neuroscience drugs. The Roche subsidiary has committed up to $53 million to collaborate with the academics on areas such as neurodegeneration over the next 10 years. [ABSTRACT FROM AUTHOR]

Atalanta Therapeutics has broken cover with $110 million from a series A round and partnerships with Biogen and Genentech. The biotech secured the deals and funding on the strength of evidence it can durably silence genes in the brain. [ABSTRACT FROM AUTHOR]

Genentech has struck a deal to license Relay Therapeutics' SHP2 inhibitor for $75 million upfront. The Roche subsidiary plans to combine the drug with its KRAS G12C inhibitor, reflecting evidence targeting SHP2 counters adaptive resistance to the red-hot approach to treating cancer. [ABSTRACT FROM AUTHOR]

Roche has bought a phase 1 pan-genotype cystic fibrosis program from Enterprise Therapeutics. The deal, which is worth £75 million ($97 million) upfront to Enterprise's shareholders, gives Roche a TMEM16A potentiator designed to restore lung function in all cystic fibrosis patients. [ABSTRACT FROM AUTHOR]

Dutch RNA specialist ProQR has hired eye disease specialist Naveed Shams, M.D., Ph.D., as its new chief scientific officer. [ABSTRACT FROM AUTHOR]

Genentech has secured a global license to neoantigen cancer vaccines developed by Vaccibody. The Roche subsidiary is set to hand over $200 million in upfront and near-term payments to access the fruits of Vaccibody's efforts to overcome the limitations of cancer vaccines. [ABSTRACT FROM AUTHOR]

Genentech is taking the ax to 474 staffers on the West Coast as it looks for a more local feel to its organization. [ABSTRACT FROM AUTHOR]

A phase 1b trial of a personalized cancer vaccine in development at Roche and BioNTech has chalked up a "low" response rate. Nine of the 108 evaluable solid tumor patients responded when given the vaccine in combination with Tecentriq, although researchers pointed to immune response results to support continued study in other populations. [ABSTRACT FROM AUTHOR]

Roche's ipatasertib has improved progression-free survival in a subgroup of prostate cancer patients in a phase 3 trial. The drug failed to improve outcomes in the broader population, but, with overall survival data still maturing, Roche thinks the findings are encouraging for its chances of claiming a slice of a market targeted by AstraZeneca. [ABSTRACT FROM AUTHOR]

Genentech has shared longer-term phase 3 safety data on its anti-IL-6 antibody satralizumab, adding to the evidence in support of the drug ahead of a FDA decision to approve it in a rare disease served by Alexion's Soliris. [ABSTRACT FROM AUTHOR]

Roche has named Aviv Regev as the new head of Genentech research and early development (gRED). Regev, who currently works at the Broad Institute, will take over as head of gRED when Michael Varney retires at the end of July. [ABSTRACT FROM AUTHOR]

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer and head of global product development at Roche. [ABSTRACT FROM AUTHOR]